Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Banking & Insurance

West Bancorporation Sets Date for Fourth Quarter and Full-Year 2025 Results

Robert Sasse by Robert Sasse
December 20, 2025
in Banking & Insurance, Dividends, Earnings
0
West Bancorporation Stock
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

Investors will get a detailed look at West Bancorporation’s financial performance later this month. The company confirmed it will release its fourth quarter and full-year 2025 earnings report before the market opens on Thursday, January 29, 2026. This announcement follows the bank’s recent recognition by Zacks Investment Research, which included it on a list of top income-generating stocks.

Earnings Call and Analyst Recognition

The formal earnings release will be followed by a conference call at 3:00 p.m. Eastern Time (2:00 p.m. Central Time) on January 29. Interested parties can join by dialing 800-715-9871 and using the conference ID 7846129. A recording of the call will be accessible until February 12, 2026.

This reporting period comes amid positive analyst sentiment. Zacks Equity Research featured the institution in a report last Friday. It had previously assigned West Bancorporation a Zacks Rank #1 (Strong Buy) on October 27, 2025. Notably, the consensus earnings estimate among Zacks-covered analysts for the current year has been revised upward by 7.4% over the past two months.

Financial Performance and Shareholder Returns

The upcoming report will build on a robust third quarter. On October 23, the company posted net income of $9.3 million, or $0.55 per diluted share. This represents a significant increase from the $6.0 million, or $0.35 per share, earned in the same quarter the previous year. A key driver was the expansion of its net interest margin to 2.36%, up from 2.27%.

Should investors sell immediately? Or is it worth buying West Bancorporation?

Shareholders currently receive a quarterly dividend of $0.25 per share. Based on recent trading prices, this provides a forward yield of approximately 4.2%, which stands well above the regional industry average yield of 2.7%.

Operational Strength and Price Action

The bank’s operations are concentrated in high-growth areas surrounding Des Moines, as well as select markets in Minnesota. Management recently described its credit quality as “extremely strong.” For the first nine months of the year, net income reached $25.1 million, compared to $17.0 million for the prior-year period.

Trading around $23.84 as of Friday’s close, the company’s shares remain comfortably above their 200-day moving average of $20.13. The central question for the January 29 release is whether the bank can meet or exceed the recently raised earnings expectations and maintain its momentum in credit quality and margins for the final quarter. No additional corporate announcements were made yesterday.

Ad

West Bancorporation Stock: Buy or Sell?! New West Bancorporation Analysis from February 7 delivers the answer:

The latest West Bancorporation figures speak for themselves: Urgent action needed for West Bancorporation investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

West Bancorporation: Buy or sell? Read more here...

Tags: West Bancorporation
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Next Post
Metaplanet Stock

Metaplanet Gains Traction with Strategic Move into US Markets

Newmont Mining Stock

Newmont Shares Extend Record Rally on Strong Fundamentals

Beyond Meat Stock

Beyond Meat Shares Surge on Speculative Trading and Options Activity

Recommended

Fiserv Stock

Fiserv Shares Struggle to Gain Traction Amid Investor Doubts

3 weeks ago
Cooper-Standard Stock

Cooper-Standard Shares Plunge on Disappointing Earnings Report

3 months ago
Volatus Aerospace Stock

Volatus Aerospace Expands Defense and Environmental Technology Operations

5 months ago
FCBC stock news

Symmetry Partners LLC Acquires Significant Position in Carnival Co. & plc, Expresses Optimism for Future Growth

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Trending

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

by Rodolfo Hanigan
February 7, 2026
0

Medical device company Embecta reported financial results for the first quarter of fiscal year 2026 on Thursday,...

Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com